**Supplementary File 3. PRACTICAL consortia authorship and acknowledgements**

**PIs from the PRACTICAL (**[**http://practical.icr.ac.uk/**](http://practical.icr.ac.uk/)**) consortia:**

Rosalind A. Eeles1,2, Christopher A. Haiman3, Zsofia Kote-Jarai1, Fredrick R. Schumacher4,5, Sara Benlloch6,1, Ali Amin Al Olama6,7, Kenneth R. Muir8, Sonja I. Berndt9, David V. Conti3, Fredrik Wiklund10, Stephen Chanock9, Ying Wang11, Catherine M. Tangen12, Jyotsna Batra13,14, Judith A. Clements13,14, APCB BioResource (Australian Prostate Cancer BioResource)15,14, Henrik Grönberg10, Nora Pashayan16,17, Johanna Schleutker18,19, Demetrius Albanes9, Stephanie Weinstein9, Alicja Wolk20, Catharine M. L. West21, Lorelei A. Mucci22, Géraldine Cancel-Tassin23,24, Stella Koutros9, Karina Dalsgaard Sørensen25,26, Eli Marie Grindedal27, David E. Neal28,29,30, Freddie C. Hamdy31,32, Jenny L. Donovan33, Ruth C. Travis34, Robert J. Hamilton35,36, Sue Ann Ingles37, Barry S. Rosenstein38, Yong-Jie Lu39, Graham G. Giles40,41,42, Robert J. MacInnis40,41, Adam S. Kibel43, Ana Vega44,45,46, Manolis Kogevinas47,48,49,50, Kathryn L. Penney51, Jong Y. Park52, Janet L. Stanford53,54, Cezary Cybulski55, Børge G. Nordestgaard56,57, Sune F. Nielsen56,57, Hermann Brenner58,59,60, Christiane Maier61, Jeri Kim62, Esther M. John63, Manuel R. Teixeira64,65,66, Susan L. Neuhausen67, Kim De Ruyck68, Azad Razack69, Lisa F. Newcomb53,70, Davor Lessel71, Radka Kaneva72, Nawaid Usmani73,74, Frank Claessens75, Paul A. Townsend76,77, Jose Esteban Castelao78, Monique J. Roobol79, Florence Menegaux80, Kay-Tee Khaw81, Lisa Cannon-Albright82,83, Hardev Pandha77, Stephen N. Thibodeau84, David J. Hunter85, Peter Kraft86, William J. Blot87,88, Elio Riboli89

1The Institute of Cancer Research, London, SM2 5NG, UK  
2Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK  
3Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA  
4Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA  
5Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA.  
6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK  
7University of Cambridge, Department of Clinical Neurosciences, Stroke Research Group, R3, Box 83, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK  
8Division of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK  
9Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA  
10Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden  
11Department of Population Science, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA  
12SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA  
13Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD 4059, Australia  
14Translational Research Institute, Brisbane, Queensland 4102, Australia  
15Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and  
16Department of Applied Health Research, University College London, London, WC1E 7HB, UK  
17Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK  
18Institute of Biomedicine, University of Turku, Finland  
19Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland  
20Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden  
21Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, M13 9PL UK  
22Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA  
23CeRePP, Tenon Hospital, F-75020 Paris, France.  
24Sorbonne Universite, GRC n°5 , AP-HP, Tenon Hospital, 4 rue de la Chine, F-75020 Paris, France  
25Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark  
26Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N  
27Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway  
28Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK  
29University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK  
30Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, CB2 0RE, UK  
31Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK  
32Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK  
33Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK  
34Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK  
35Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9, Canada  
36Dept. of Surgery (Urology), University of Toronto, Canada  
37Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA  
38Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA  
39Centre for Cancer Biomarker and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK  
40Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia  
41Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia  
42Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia  
43Division of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA  
44Fundación Pública Galega Medicina Xenómica, Santiago de Compostela, 15706, Spain.  
45Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, 15706, Spain.  
46Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain  
47ISGlobal, Barcelona, Spain  
48IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain  
49Universitat Pompeu Fabra (UPF), Barcelona, Spain  
50CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain  
51Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02115, USA  
52Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA  
53Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, USA  
54Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA  
55International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland  
56Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
57Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark  
58Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany  
59German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany  
60Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany  
61Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany  
62The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA  
63Departments of Epidemiology & Population Health and of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304 USA  
64Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal  
65Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal  
66Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal  
67Department of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, 626-256-HOPE (4673)  
68Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Proeftuinstraat 86, B-9000 Gent  
69Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia  
70Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA  
71Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany  
72Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria  
73Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2  
74Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2  
75Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Belgium  
76Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, Univeristy of Manchester, M13 9WL  
77The University of Surrey, Guildford, Surrey, GU2 7XH, UK  
78Genetic Oncology Unit, CHUVI Hospital, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), 36204, Vigo (Pontevedra), Spain  
79Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands  
80"Exposome and Heredity", CESP (UMR 1018), Faculté de Médecine, Université Paris-Saclay, Inserm, Gustave Roussy, Villejuif  
81Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK  
82Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA  
83George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA  
84Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA  
85Nuffield Department of Population Health, University of Oxford, United Kingdom  
86Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA  
87Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37232 USA.  
88International Epidemiology Institute, Rockville, MD 20850, USA  
89Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, SW7 2AZ, UK

**CRUK and PRACTICAL consortium Funding Acknowledgements:**

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Manchester NIHR Biomedical Research Centre. The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Research reported in this publication also received support from the National Cancer Institute of the National Institutes of Health under Award Numbers U10 CA37429 (CD Blanke), and UM1 CA182883 (CM Tangen/IM Thompson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.